Company news
Resverlogix Corp. news in 2016
Resverlogix Corp.'s news releases, calls and decks from 2016, newest first.
Resverlogix Announces Voting Results From The 2016 Annual And Special Meeting Of Shareholders
December 15, 2016
Resverlogix Announces Second Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)
December 5, 2016
Resverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase 2 Studies
November 17, 2016
Resverlogix Announces Annual and Special Meeting of Shareholders
October 6, 2016
Resverlogix To Host Research & Development Update Featuring Key Opinion Leaders in Cardiovascular and Renal Disease
October 4, 2016
Resverlogix Announces Participation in Upcoming Conferences
September 12, 2016
Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy
August 29, 2016
Resverlogix Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)
August 11, 2016
Resverlogix Files 2016 Year-End Disclosure Documents
July 27, 2016
Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs
July 21, 2016
Resverlogix Announces Corporate Update Webcast
June 9, 2016
Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2016
June 2, 2016
Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)
May 24, 2016
The New York Academy of Sciences Collaborates with Resverlogix to Host Epigenetics Symposium
April 18, 2016
Resverlogix Further Strengthens the Board of Directors and Appoints a New Chairman
April 4, 2016
Resverlogix's Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal
January 25, 2016